Advertisement
Advertisement
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
PremiumThe FlyAligos Therapeutics announces inducement grants under Nasdaq listing rule
27d ago
Aligos Therapeutics receives USAN council approval for pevifoscorvir sodium
Premium
The Fly
Aligos Therapeutics receives USAN council approval for pevifoscorvir sodium
28d ago
Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
Premium
Ratings
Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
1M ago
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
PremiumThe FlyAligos Therapeutics announces inducement grants under Nasdaq listing rule
3M ago
Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study
Premium
The Fly
Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study
3M ago
Aligos Therapeutics Reports Q2 2025 Progress and Results
Premium
Company Announcements
Aligos Therapeutics Reports Q2 2025 Progress and Results
3M ago
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
PremiumThe FlyAligos Therapeutics announces inducement grants under Nasdaq listing rule
5M ago
Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal
Premium
The Fly
Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal
6M ago
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
Premium
The Fly
Aligos Therapeutics announces inducement grants under Nasdaq listing rule
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100